West
California
California applies a stricter compounding posture through the Sherman Food, Drug, and Cosmetic Law and aggressive board oversight.
Legal context
California pharmacies typically face the most conservative interpretation when a peptide lacks clear federal support for compounding.
What this means
Expect pharmacies to avoid Category 2 peptides even when marketed as wellness therapies.
Clinical demand alone is unlikely to overcome a missing USP monograph or FDA-approved pathway.
Patients frequently need to look outside California for legal alternatives such as Sermorelin or PT-141.